Biologics

Biologics clinical programs add complexity around product handling, immunogenicity, and safety signal interpretation that small-molecule teams may not face daily. Viltis supports sponsors developing monoclonal antibodies, cell and gene therapies, vaccines, and other biologic modalities through phases of clinical evaluation under ICH GCP. We focus on study operations that respect cold-chain and chain-of-identity constraints while keeping protocol execution and data quality intact. Early conversations usually cover site capability, specialty lab capacity, and how product accountability will be documented in source and the TMF.

Early biologic trials often run with limited site networks, specialized procedures, and dense safety follow-up. We help teams set monitoring intensity, laboratory vendor oversight, and pharmacokinetic or pharmacodynamic sampling logistics that match the protocol. For advanced therapies, we also look at site readiness for product receipt, preparation, and administration documentation that inspectors will expect to see. Visit windows, sample kits, and courier plans are treated as study-critical controls, not secondary logistics.

As programs move into larger confirmatory studies, the pressure shifts to enrollment across more sites, consistent endpoint assessment, and clean datasets for BLA or MAA packages. Our consultants support clinical operations, data review coordination, and inspection readiness without claiming manufacturing or CMC ownership that belongs elsewhere on the program. When immunogenicity or infusion reactions drive protocol questions, we help clinical and safety teams keep reporting and monitoring instructions consistent for sites.

Biologic studies also benefit from early alignment between clinical ops, medical monitoring, and data management on what constitutes a protocol deviation versus expected product-related procedure variation. That clarity reduces noise in deviation listings and keeps CAPA effort focused on true risk to participants or data integrity. Clear written instructions for sites on product handling and reporting thresholds prevent mixed messages during enrollment ramps.

Biologics clinical consulting commonly covers

• Protocol feasibility for biologic-specific procedures
• Site readiness for product handling and administration
• Immunogenicity and specialty lab vendor oversight
• Safety signal review workflows with clinical ops
• Monitoring plans for high-complexity visit schedules
• TMF documentation for product accountability
• BLA or MAA clinical package inspection prep

When a biologic study is strained by site capability, sample logistics, or unclear ownership between clinical and CMC teams, we help clarify roles and tighten the operational controls that keep the trial credible.